Drug

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

Congress: CLINAM, 23rd May 2011 – The development of new activatable drug nanocarriers, with multiple functionalities, presents a promising approach for cancer treatment. Improved drug delivery and controlled drug release at the tumor site may have considerable benefit by increasing treatment efficacy while reducing side effects and toxicity. Further, the possibility to monitor both nanocarrier accumulation and drug release via current clinical imaging techniques may be particularly relevant for an optimal treatment.

Continue Reading...

2017 – Nano-sized cytochrome p450 3a4 inhibitors to block hepatic – Paolini et al.

Most drugs are metabolized by hepatic cytochrome P450 3A4 (CYP3A4), resulting in their reduced bioavailability. In this study, we present the design and evaluation of biocompatible nanocarriers trapping a natural CYP3A4-inhibiting compound. Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic CYP3A4 and leave drug-metabolizing enzymes in other organs undisturbed.

Continue Reading...

2010 – Combinations of proteins with Nano-Systems – Di Marco et al.

The latest development of protein engineering allows the production of proteins having desired properties and large potential markets, but the clinical advances of therapeutical proteins are still limited by their fragility. Nanotechnology could provide optimal vectors able to protect from degradation therapeutical biomolecules such as proteins, enzymes or specific polypeptides.

Continue Reading...